European biotechs migrate to Boston area

France's Cytoo Cell Architects has set up a small subsidiary in Framingham, Massachusetts. The biotech company was lured to the Boston-area biotech hub as it expands its work on analysis and cell screening. The Boston Globe notes that this is the third European biotech to establish operations in the state in the past two months. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.